Timothy Chan

Timothy Chan has led Friends of Cancer Research (FOCR) efforts to harmonize tumor mutational burden thresholds across different clinical genomic platforms and has contributed foundational studies on neoantigen prediction and immunogenicity models. His research examines blood-based TMB as an alternative to tissue TMB for IO biomarker assessment and the relationship between TMB thresholds and clinical benefit across tumor types. He contributed to the validation frameworks underlying FDA consideration of TMB as a companion diagnostic. Chan is recognized internationally for his translational work bridging computational genomics and clinical immunotherapy biomarker development.